Arena Pharmaceuticals reported that data from its Phase III trial demonstrates lorcaserin significantly increased excess weight loss and was not associated with depression.
The Behavioral modification and Lorcaserin for Overweight and Obesity Management or BLOOM trial showed that lorcaserin also improved markers of cardiovascular risk and glycaemic parameters.
Additional subgroup analyses showed that lorcaserin caused the greatest improvements in lipid profiles, glycaemic parameters and other markers of cardiovascular risk in patients in the highest risk categories, the company said.
Florida Hospital Translational Research Institute for Metabolism and Diabetes executive director Steven Smith said that the study showed significant reduction in excess weight over one year, while improving important risk factors and quality of life.
“There is an enormous unmet need for new weight management treatments to help address the obesity epidemic. If approved, lorcaserin’s unique combination of efficacy, safety and tolerability will make it suitable as first-line therapy for weight management,” Smith said.